Sign in

    Esperion Therapeutics Inc (ESPR)

    You might also like

    Business Description

    Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company aims to address unmet needs in the treatment of atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) through innovative therapies. Esperion sells medications such as NEXLETOL and NEXLIZET, which are designed to lower LDL-C levels in adults with primary hyperlipidemia.

    1. Collaboration Revenue - Generates income through agreements with international partners, including product sales and royalties.
    2. Product Sales - Sells medications like NEXLETOL and NEXLIZET, which are used to lower LDL-C in adults with primary hyperlipidemia.

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Sheldon L. KoenigPresident and CEOMay 2021Sheldon L. Koenig has served as the President and Chief Executive Officer of Esperion Therapeutics, Inc. since May 2021. He was also appointed to the company's Board of Directors in the same month. Prior to this role, he served as Esperion's Chief Operating Officer starting in December 2020.
    JoAnne FoodyChief Medical OfficerJune 2021JoAnne Foody, M.D., FACC, FAHA, has served as the Chief Medical Officer of Esperion Therapeutics since June 2021. Prior to joining Esperion, she held roles of increasing responsibility at Johnson & Johnson's Janssen Pharmaceutical Company from November 2016 to June 2021.
    Benjamin HalladayChief Financial OfficerNov 2022Benjamin Halladay has served as the Chief Financial Officer of Esperion Therapeutics, Inc. since November 2022. He joined the company in January 2020, holding various roles including Senior Director of Financial Planning and Analysis (from August 2022 to November 2022).
    Benjamin LookerGeneral CounselJan 2022Benjamin Looker has served as the General Counsel of Esperion Therapeutics, Inc. since January 1, 2022. Prior to joining Esperion, he was the General Counsel of Trillium Therapeutics from April 2021 until its acquisition by Pfizer Inc. in November 2021.
    Eric WarrenChief Commercial OfficerMar 2022Eric Warren has served as the Chief Commercial Officer of Esperion Therapeutics since March 2022. Prior to this role, he was the company's Vice President, US Sales and Marketing from January 2021 to March 2022.

    Questions to Ask Management

    1. Can you provide more details on the gross-to-net headwinds you're experiencing due to the recent Medicare contracts, and how do you anticipate these will impact net pricing and profitability in the coming quarters?
    2. With the expansion to over 165 million patient lives under the new utilization management criteria, have you had to make significant concessions or pricing adjustments to achieve this coverage, and do you expect further concessions to secure additional contracts?
    3. Despite the reported double-digit growth in prescriptions, what challenges do you foresee in maintaining this momentum, especially considering potential headwinds such as the Medicare coverage gap and the upcoming IRA changes?
    4. Given the 20% increase in selling, general and administrative expenses due to higher commercial headcount and promotional costs, how do you plan to manage SG&A expenses moving forward to ensure profitability if revenue growth does not meet expectations?
    5. Could you elaborate on the expected financial contributions and timelines from your international partnerships, particularly with Otsuka in Japan, and how potential delays or challenges in these markets might affect your overall financial outlook?